Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis.
Kasia Owczarczyk,Matthew D Cascino,Cecile T.J. Holweg,Gaik W. Tew,Ward Ortmann,Timothy W. Behrens,Thomas Schindler,Carol A. Langford,E. William St. Clair,Peter A. Merkel,Robert Spiera,Philip Seo,Cees G. M. Kallenberg,Ulrich Specks,Noha Lim,John H. Stone,Paul Brunetta,Marco Prunotto +17 more
TL;DR: The data taken together suggest that FCRL5 is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner.
read more
Abstract: BACKGROUNDBaseline expression of FCRL5, a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical response to RTX in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).METHODSA previously validated quantitative PCR-based (qPCR-based) platform was used to assess FCRL5 expression in patients with GPA/MPA (RAVE trial, NCT00104299).RESULTSBaseline FCRL5 expression was significantly higher in patients achieving complete remission (CR) at 6, 12, and 18 months, independent of other clinical and serological variables, among those randomized to RTX but not cyclophosphamide-azathioprine (CYC/AZA). Patients with baseline FCRL5 expression ≥ 0.01 expression units (termed FCRL5hi) exhibited significantly higher CR rates at 6, 12, and 18 months as compared with FCRL5lo subjects (84% versus 57% [P = 0.016], 68% versus 40% [P = 0.02], and 68% versus 29% [P = 0.0009], respectively).CONCLUSIONOur data taken together suggest that FCRL5 is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner.FUNDINGThe analysis for this study was funded by Genentech Inc.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases
Kentaro Hata,Toyoshi Yanagihara,Keisuke Matsubara,Kazufumi Kunimura,Kunihiro Suzuki,Kazuya Tsubouchi,Daisuke Eto,Hiroyuki Ando,Maki Uehara,Satoshi Ikegame,Yoshihiro Baba,Yoshinori Fukui,Isamu Okamoto +12 more
TL;DR: In this article , a mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid (BALF) from patients with idiopathic pulmonary fibrosis (IPF), connective-tissue disease (CTD)-related ILD, and sarcoidosis, using two panels including 64 markers.
24
Variants of Novel Immunomodulatory Fc Receptor Like 5 Gene Are Associated With Multiple Sclerosis Susceptibility in the Polish Population.
Monika Chorazy,Natalia Wawrusiewicz-Kurylonek,Edyta Adamska-Patruno,Agata Czarnowska,Olga Zajkowska,Katarzyna Kapica-Topczewska,Renata Posmyk,Adam Kretowski,Jan Kochanowicz,Alina Kułakowska +9 more
TL;DR: In this article, the authors used the chi-squared test confirmed with Fisher's exact test to test whether some single nucleotide variants in the FCRL5 gene were associated with multiple sclerosis susceptibility and clinical manifestations in the Polish population.
Monitoring disease activity in antineutrophil antibody‐associated vasculitis
TL;DR: In this article , the authors overviewed the most interesting biomarkers reported so far for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).
5
Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases
Toyoshi Yanagihara
- 15 Jan 2023
TL;DR: In this paper , the authors conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid (BALF) from patients with idiopathic pulmonary fibrosis (IPF), connective-tissue disease (CTD)-related ILD, and sarcoidosis, using two panels including 64 markers.
Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis
08 Jun 2023
TL;DR: In this paper , a mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid from patients with pneumocystis jirovecii pneumonia (PCP), cytotoxic drug-induced interstitial lung diseases (DI-ILD), and ICI-associated ILD (ICI-ILD) using two panels containing 64 markers.
2
References
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
Efficacy of Remission-Induction Regimens for ANCA-associated Vasculitis
Ulrich Specks,Peter A. Merkel,Philip Seo,Robert Spiera,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Barri J. Fessler,Linna Ding,Lisa Viviano,Nadia K. Tchao,Deborah Phippard,Adam Asare,Noha Lim,David Ikle,Brett Jepson,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Mark Mueller,Lourdes P. Sejismundo,Kathleen Mieras,John H. Stone +30 more
TL;DR: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months.
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis
Susan L. Hogan,Ronald J. Falk,Hyunsook Chin,Jianwen Cai,Caroline E. Jennette,J. Charles Jennette,Patrick H. Nachman +6 more
TL;DR: A large cohort of patients with ANCA-associated glomerulonephritis and vasculitis was recruited to determine which patients were more likely to relapse; the impact of relapse on long-term outcome; the correlation between length of immunosuppressive therapy and the likelihood of relapse; and the viability of discontinuing immunomodulating therapy in patients who have attained remission.
487
A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score
John H. Stone,Gary S. Hoffman,Peter A. Merkel,Yuan I. Min,Misty L. Uhlfelder,David B. Hellmann,Ulrich Specks,Nancy B. Allen,John C. Davis,Robert Spiera,Leonard H. Calabrese,Fredrick M. Wigley,Nicola Maiden,R. Valente,John L. Niles,Kenneth H. Fye,Joseph W. McCune,E. William St. Clair,Raashid Luqmani +18 more
TL;DR: The Birmingham Vasculitis Activity Score (BVAS) is a valid, disease-specific activity index for Wegener's granulomatosis (WG), which correlates well with the PGA, is sensitive to change, and has good inter- and intraobserver reliability.
485
Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease
J. Charles Jennette,Ronald Falk +1 more
TL;DR: Clinical and experimental evidence supports a pathogenesis that is driven by ANCA-induced activation of neutrophils and monocytes, producing destructive necrotizing vascular and extravascular inflammation.
440
Related Papers (5)
Martin Weisser,Ru-Fang Yeh,Guillemette Duchateau-Nguyen,Giuseppe Palermo,Tri Quang Nguyen,Xiaoyan Shi,Susanna Stinson,Nancy Yu,Annika Dufour,Tadeusz Robak,Galina Salogub,Anna Dmoszynska,Philippe Solal-Celigny,Krzysztof Warzocha,Javier Loscertales,John Catalano,Loree Larratt,Viktor Rossiev,Isabelle Bence-Bruckler,Christian H. Geisler,Marco Montillo,Kirsten Fischer,Anna-Maria Fink,Michael Hallek,Johannes Bloehdorn,Raymonde Busch,Axel Benner,Hartmut Döhner,Nancy Valente,Michael Wenger,Stephan Stilgenbauer,David Dornan +31 more